JANX Stock: Price, Earnings History and SEC Filings
Janux Therapeutics, Inc. (JANX) last traded at $17.47, down 2.02% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.35 against an analyst estimate of $-0.26, a miss of 34.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
JANX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.35 | $-0.26 | -34.62% |
| Mar 2026 | May 7, 2026 | $-0.39 | $-0.50 | +22.00% |
| Dec 2025 | Feb 26, 2026 | $-0.51 | $-0.65 | +21.54% |
| Sep 2025 | Nov 6, 2025 | $-0.39 | $-0.60 | +35.00% |
JANX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How JANX reacts to earnings
Across its last 8 earnings releases, JANX moved 2.7% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | -1.55% |
| 2026-05-07 | After close | -2.51% |
| 2026-02-26 | After close | -1.38% |
| 2025-11-06 | After close | -7.61% |
| 2025-08-07 | After close | +1.11% |
| 2025-05-08 | After close | -3.07% |
| 2025-02-27 | After close | +2.75% |
| 2024-11-06 | After close | -1.24% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
JANX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $10M | -$114M | -$83M | -1136.3% | $-1.83 |
| 2024 | $11M | -$69M | -$44M | -651.6% | $-1.28 |
| 2023 | $8M | -$58M | -$52M | -721.2% | $-1.32 |
| 2022 | $9M | -$63M | -$49M | -732.2% | $-1.52 |
| 2021 | $4M | -$33M | -$18M | -898.3% | $-1.39 |
| 2020 | $0 | -$7M | -$4M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for JANX
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 23, 2026Other events
- 8-K · Jun 12, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 28, 2026Officer or director change
- DEF 14A · Apr 28, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 26, 2026Results of operations, Financial statements and exhibits
Insider filing activity
JANX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
JANX news
- Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On SalesOct 29, 2026 · finance.yahoo.com
- Ensign Group (ENSG) Beats Q3 Earnings EstimatesOct 27, 2026 · finance.yahoo.com
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.